Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможности и перспективы локального применения гиалуроновой кислоты при вульвовагинальной атрофии у женщин репродуктивного возраста
Возможности и перспективы локального применения гиалуроновой кислоты при вульвовагинальной атрофии у женщин репродуктивного возраста
Прилепская В.Н., Назарова Н.М., Девяткина А.Р., Абакарова П.Р., Межевитинова Е.А. Возможности и перспективы локального применения гиалуроновой кислоты при вульвовагинальной атрофии у женщин репродуктивного возраста. Гинекология. 2024;26(3):254–259. DOI: 10.26442/20795696.2024.3.202932
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Нарушение структуры и функции вульвовагинального эпителия у женщин репродуктивного возраста сопровождается снижением сексуальной функции и качества жизни. В представленном обзоре проведен анализ данных исследований по применению гиалуроновой кислоты (ГК) у женщин репродуктивного возраста с различными состояниями и заболеваниями, проявляющимися вульвовагинальной атрофией. ГК участвует в различных физиологических процессах в организме, регенерации тканей, миграции и пролиферации клеток при воспалении, помогает поддерживать водный баланс и целостность структуры тканей. Локальная терапия ГК эффективна в отношении всех симптомов вульвовагинальной атрофии у женщин репродуктивного возраста, связанных с гипоэстрогенией, как в форме монотерапии, так и при комбинированном лечении, способствуя улучшению сексуальной функции и повышению качества жизни.
Ключевые слова: вульвовагинальная атрофия, гиалуроновая кислота, генитоуринарный менопаузальный синдром, дерматозы, внутриматочные синехии
Keywords: vulvovaginal atrophy, hyaluronic acid, genitourinary menopausal syndrome, dermatoses, intrauterine adhesions
Ключевые слова: вульвовагинальная атрофия, гиалуроновая кислота, генитоуринарный менопаузальный синдром, дерматозы, внутриматочные синехии
________________________________________________
Keywords: vulvovaginal atrophy, hyaluronic acid, genitourinary menopausal syndrome, dermatoses, intrauterine adhesions
Полный текст
Список литературы
1. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-8. DOI:10.1097/GME.0000000000000329
2. Lev-Sagie A. Vulvar and vaginal atrophy: Physiology, clinical presentation, and treatment considerations. Clin Obs Gynecol. 2015;58(3):476-91. DOI:10.1097/GRF.0000000000000126
3. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. DOI:10.4065/mcp.2009.0413
4. Alvisi S, Gava G, Orsili I, et al. Vaginal health in menopausal women. Medicina (Kaunas). 2019;55(10):615. DOI:10.3390/medicina55100615
5. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62(4 Suppl. 1):45-51. DOI:10.1016/s0090-4295(03)00676-9
6. Escobar C, Rosenblum N. Vaginal estrogen – what a urologist should know. Urology. 2021;151:37-43. DOI:10.1016/j.urology.2020.05.034
7. Bayer IS. Hyaluronic acid and controlled release: A review. Molecules. 2020;25(11):2649. DOI:10.3390/molecules25112649
8. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528-39. DOI:10.1038/nrc1391
9. Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018;10(7):701. DOI:10.3390/polym10070701
10. Leeman LM, Rogers RG. Sex after childbirth: Postpartum sexual function. Obstet Gynecol. 2012;119(3):647-55. DOI:10.1097/AOG.0b013e3182479611
11. Banaei M, Azizi M, Moridi A, et al. Sexual dysfunction and related factors in pregnancy and postpartum: A systematic review and meta-analysis protocol. Syst Rev. 2019;8(1):161. DOI:10.1186/s13643-019-1079-4
12. Rowland M, Foxcroft L, Hopman WM, Patel R. Breastfeeding and sexuality immediately postpartum. Can Fam Physician. 2005;51(10):1366-7. PMID:16926969
13. Agarwal SK, Kim J, Korst LM, Hughes CL. Application of the estrogen threshold hypothesis to the physiologic hypoestrogenemia of lactation. Breastfeed Med. 2015;10(2):77-83. DOI:10.1089/bfm.2014.0030
14. Gustavino C, Sala P, Cusini N, et al. Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: A prospective randomised clinical trial. Ann Med. 2021;53(1):1589-97. DOI:10.1080/07853890.2021.1974083
15. Менопауза и климактерическое состояние у женщины. Клинические рекомендации РОАГ. 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/117_2. Ссылка активна на 16.05.2024 [Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Klinicheskie rekomendatsii ROAG. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/117_2. Accessed: 16.05.2024 (in Russian)].
16. Ekin M, Yaşar L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet. 2011;283(3):539-43. DOI:10.1007/s00404-010-1382-8
17. Jokar A, Davari T, Asadi N, et al. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: A randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016;4(1):69-78. PMID:26793732
18. Cox P, Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019;22(6):565-71. DOI:10.1080/13697137.2019.1643180
19. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74(3):220-3. DOI:10.1016/j.contraception.2006.03.022
20. Handy AB, McMahon LN, Goldstein I, Meston CM. Reduction in genital sexual arousal varies by type of oral contraceptive pill. J Sex Med. 2023;20(8):1094-102. doi:10.1093/jsxmed/qdad072
21. Cotangco K, Class QA, Johnson TP, Kothari R. Cervical cancer survivors' attitudes and understanding of menopause and hormone therapy. Menopause. 2020;27(6):701-5. DOI:10.1097/GME.0000000000001520
22. Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: Incidence and survival across European Countries. Breast Care (Basel). 2019;14(6):344-53. DOI:10.1159/000503219
23. Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol. 2022;13(2):71-100. DOI:10.5306/wjco.v13.i2.71
24. Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647-61. DOI:10.1210/jc.2017-01138
25. Kingsberg SA, Larkin L, Krychman M, et al. WISDOM survey: Attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. 2019;26(2):124-31. DOI:10.1097/GME.0000000000001194
26. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. DOI:10.1097/GME.0000000000001609
27. Shah MB, Hoffstetter S. Contraception and sexuality. Minerva Ginecol. 2010;62(4):331-47. PMID:20827250
28. Casey PM, MacLaughlin KL, Faubion SS. Impact of contraception on female sexual function. J Womens Health (Larchmt). 2017;26(3):207-13. DOI:10.1089/jwh.2015.5703
29. Журавлева Ю.А., Прохорова О.В., Гептинг Н.А., и др. Женская сексуальность и комбинированные оральные контрацептивы: проблемы и возможности коррекции. Российский вестник акушера-гинеколога. 2020;20(6):101-6 [Zhuravleva JA, Prokhorova OV, Gepting NA, et al. Female sexuality and combined oral contraceptive pills: Administration and correction issues. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(6):101-6 (in Russian)]. DOI:10.17116/rosakush202020061101
30. Krapf JM, Mitchell L, Holton MA, Goldstein AT. Vulvar lichen sclerosus: Current perspectives. Int J Womens Health. 2020;12:11-20. DOI:10.2147/IJWH.S191200
31. Singh N, Ghatage P. Etiology, clinical features, and diagnosis of vulvar lichen sclerosus: A scoping review. Obstet Gynecol Int. 2020;2020:7480754. DOI:10.1155/2020/7480754
32. Шперлинг Н.В., Шперлинг М.И. Лечение и профилактика рецидивирования склероатрофического лихена половых органов у женщин. Акушерство и гинекология. 2022;12:70-8 [Shperling NV, Shperling MI. Treatment and prevention of recurrent genital lichen sclerosus in women. Obstetrics and Gynecology. 2022;12:70-8 (in Russian)]. DOI:10.18565/aig.2022.280
33. Van der Meijden WI, Boffa MJ, Ter Harmsel B, et al. 2021 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2022;36(7):952-72. DOI:10.1111/jdv.18102
34. Лишай красный плоский. Клинические рекомендации. 2020. Режим доступа: https://cnikvi.ru/docs/klinicheskie-rekomendacii/КР%20КПЛ%202020.docx. Ссылка активна на 16.05.2024 [Lishai krasnyi ploskii. Klinicheskie rekomendatsii. 2020. Available at: https://cnikvi.ru/docs/klinicheskie-rekomendacii/КР%20КПЛ%202020.docx. Accessed: 16.05.2024 (in Russian)].
35. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-6. DOI:10.1046 j.1365-2133.2000.03473.x
36. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808-14. DOI:10.1111/j.1365-2133.2011.10449.x
37. Dreisler E, Kjer JJ. Asherman's syndrome: Current perspectives on diagnosis and management. Int J Womens Health. 2019;11:191-8. DOI:10.2147/IJWH.S165474
38. Lee WL, Liu CH, Cheng M, et al. Focus on the primary prevention of intrauterine adhesions: Current concept and vision. Int J Mol Sci. 2021;22(10):5175. DOI:10.3390/ijms22105175
39. Tafti SZG, Javaheri A, Firoozabadi RD, et al. Role of hyaluronic acid intrauterine injection in the prevention of Asherman's syndrome in women undergoing uterine septum resection: An RCT. Int J Reprod Biomed. 2021;19(4):339-46. DOI:10.18502/ijrm.v19i4.9060
40. Huang CY, Chang WH, Cheng M, et al. Crosslinked hyaluronic acid gels for the prevention of intrauterine adhesions after a hysteroscopic myomectomy in women with submucosal myomas: A prospective, randomized, controlled trial. Life (Basel). 2020;10(5):67. DOI:10.3390life10050067
41. Wang YQ, Song XH, Wu SL, et al. Comparison of autocross-linked hyaluronic acid gel and intrauterine device for preventing intrauterine adhesions in infertile patients: A randomized clinical trial. Gynecol Minim Invasive Ther. 2020;9(2):74-80. DOI:10.4103/GMIT.GMIT_103_19
2. Lev-Sagie A. Vulvar and vaginal atrophy: Physiology, clinical presentation, and treatment considerations. Clin Obs Gynecol. 2015;58(3):476-91. DOI:10.1097/GRF.0000000000000126
3. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. DOI:10.4065/mcp.2009.0413
4. Alvisi S, Gava G, Orsili I, et al. Vaginal health in menopausal women. Medicina (Kaunas). 2019;55(10):615. DOI:10.3390/medicina55100615
5. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62(4 Suppl. 1):45-51. DOI:10.1016/s0090-4295(03)00676-9
6. Escobar C, Rosenblum N. Vaginal estrogen – what a urologist should know. Urology. 2021;151:37-43. DOI:10.1016/j.urology.2020.05.034
7. Bayer IS. Hyaluronic acid and controlled release: A review. Molecules. 2020;25(11):2649. DOI:10.3390/molecules25112649
8. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528-39. DOI:10.1038/nrc1391
9. Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018;10(7):701. DOI:10.3390/polym10070701
10. Leeman LM, Rogers RG. Sex after childbirth: Postpartum sexual function. Obstet Gynecol. 2012;119(3):647-55. DOI:10.1097/AOG.0b013e3182479611
11. Banaei M, Azizi M, Moridi A, et al. Sexual dysfunction and related factors in pregnancy and postpartum: A systematic review and meta-analysis protocol. Syst Rev. 2019;8(1):161. DOI:10.1186/s13643-019-1079-4
12. Rowland M, Foxcroft L, Hopman WM, Patel R. Breastfeeding and sexuality immediately postpartum. Can Fam Physician. 2005;51(10):1366-7. PMID:16926969
13. Agarwal SK, Kim J, Korst LM, Hughes CL. Application of the estrogen threshold hypothesis to the physiologic hypoestrogenemia of lactation. Breastfeed Med. 2015;10(2):77-83. DOI:10.1089/bfm.2014.0030
14. Gustavino C, Sala P, Cusini N, et al. Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: A prospective randomised clinical trial. Ann Med. 2021;53(1):1589-97. DOI:10.1080/07853890.2021.1974083
15. Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Klinicheskie rekomendatsii ROAG. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/117_2. Accessed: 16.05.2024 (in Russian).
16. Ekin M, Yaşar L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet. 2011;283(3):539-43. DOI:10.1007/s00404-010-1382-8
17. Jokar A, Davari T, Asadi N, et al. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: A randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016;4(1):69-78. PMID:26793732
18. Cox P, Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019;22(6):565-71. DOI:10.1080/13697137.2019.1643180
19. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74(3):220-3. DOI:10.1016/j.contraception.2006.03.022
20. Handy AB, McMahon LN, Goldstein I, Meston CM. Reduction in genital sexual arousal varies by type of oral contraceptive pill. J Sex Med. 2023;20(8):1094-102. doi:10.1093/jsxmed/qdad072
21. Cotangco K, Class QA, Johnson TP, Kothari R. Cervical cancer survivors' attitudes and understanding of menopause and hormone therapy. Menopause. 2020;27(6):701-5. DOI:10.1097/GME.0000000000001520
22. Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: Incidence and survival across European Countries. Breast Care (Basel). 2019;14(6):344-53. DOI:10.1159/000503219
23. Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol. 2022;13(2):71-100. DOI:10.5306/wjco.v13.i2.71
24. Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647-61. DOI:10.1210/jc.2017-01138
25. Kingsberg SA, Larkin L, Krychman M, et al. WISDOM survey: Attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. 2019;26(2):124-31. DOI:10.1097/GME.0000000000001194
26. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. DOI:10.1097/GME.0000000000001609
27. Shah MB, Hoffstetter S. Contraception and sexuality. Minerva Ginecol. 2010;62(4):331-47. PMID:20827250
28. Casey PM, MacLaughlin KL, Faubion SS. Impact of contraception on female sexual function. J Womens Health (Larchmt). 2017;26(3):207-13. DOI:10.1089/jwh.2015.5703
29. Zhuravleva JA, Prokhorova OV, Gepting NA, et al. Female sexuality and combined oral contraceptive pills: Administration and correction issues. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(6):101-6 (in Russian). DOI:10.17116/rosakush202020061101
30. Krapf JM, Mitchell L, Holton MA, Goldstein AT. Vulvar lichen sclerosus: Current perspectives. Int J Womens Health. 2020;12:11-20. DOI:10.2147/IJWH.S191200
31. Singh N, Ghatage P. Etiology, clinical features, and diagnosis of vulvar lichen sclerosus: A scoping review. Obstet Gynecol Int. 2020;2020:7480754. DOI:10.1155/2020/7480754
32. Shperling NV, Shperling MI. Treatment and prevention of recurrent genital lichen sclerosus in women. Obstetrics and Gynecology. 2022;12:70-8 (in Russian). DOI:10.18565/aig.2022.280
33. Van der Meijden WI, Boffa MJ, Ter Harmsel B, et al. 2021 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2022;36(7):952-72. DOI:10.1111/jdv.18102
34. Lishai krasnyi ploskii. Klinicheskie rekomendatsii. 2020. Available at: https://cnikvi.ru/docs/klinicheskie-rekomendacii/КР%20КПЛ%202020.docx. Accessed: 16.05.2024 (in Russian).
35. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-6. DOI:10.1046 j.1365-2133.2000.03473.x
36. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808-14. DOI:10.1111/j.1365-2133.2011.10449.x
37. Dreisler E, Kjer JJ. Asherman's syndrome: Current perspectives on diagnosis and management. Int J Womens Health. 2019;11:191-8. DOI:10.2147/IJWH.S165474
38. Lee WL, Liu CH, Cheng M, et al. Focus on the primary prevention of intrauterine adhesions: Current concept and vision. Int J Mol Sci. 2021;22(10):5175. DOI:10.3390/ijms22105175
39. Tafti SZG, Javaheri A, Firoozabadi RD, et al. Role of hyaluronic acid intrauterine injection in the prevention of Asherman's syndrome in women undergoing uterine septum resection: An RCT. Int J Reprod Biomed. 2021;19(4):339-46. DOI:10.18502/ijrm.v19i4.9060
40. Huang CY, Chang WH, Cheng M, et al. Crosslinked hyaluronic acid gels for the prevention of intrauterine adhesions after a hysteroscopic myomectomy in women with submucosal myomas: A prospective, randomized, controlled trial. Life (Basel). 2020;10(5):67. DOI:10.3390life10050067
41. Wang YQ, Song XH, Wu SL, et al. Comparison of autocross-linked hyaluronic acid gel and intrauterine device for preventing intrauterine adhesions in infertile patients: A randomized clinical trial. Gynecol Minim Invasive Ther. 2020;9(2):74-80. DOI:10.4103/GMIT.GMIT_103_19
2. Lev-Sagie A. Vulvar and vaginal atrophy: Physiology, clinical presentation, and treatment considerations. Clin Obs Gynecol. 2015;58(3):476-91. DOI:10.1097/GRF.0000000000000126
3. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. DOI:10.4065/mcp.2009.0413
4. Alvisi S, Gava G, Orsili I, et al. Vaginal health in menopausal women. Medicina (Kaunas). 2019;55(10):615. DOI:10.3390/medicina55100615
5. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62(4 Suppl. 1):45-51. DOI:10.1016/s0090-4295(03)00676-9
6. Escobar C, Rosenblum N. Vaginal estrogen – what a urologist should know. Urology. 2021;151:37-43. DOI:10.1016/j.urology.2020.05.034
7. Bayer IS. Hyaluronic acid and controlled release: A review. Molecules. 2020;25(11):2649. DOI:10.3390/molecules25112649
8. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528-39. DOI:10.1038/nrc1391
9. Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018;10(7):701. DOI:10.3390/polym10070701
10. Leeman LM, Rogers RG. Sex after childbirth: Postpartum sexual function. Obstet Gynecol. 2012;119(3):647-55. DOI:10.1097/AOG.0b013e3182479611
11. Banaei M, Azizi M, Moridi A, et al. Sexual dysfunction and related factors in pregnancy and postpartum: A systematic review and meta-analysis protocol. Syst Rev. 2019;8(1):161. DOI:10.1186/s13643-019-1079-4
12. Rowland M, Foxcroft L, Hopman WM, Patel R. Breastfeeding and sexuality immediately postpartum. Can Fam Physician. 2005;51(10):1366-7. PMID:16926969
13. Agarwal SK, Kim J, Korst LM, Hughes CL. Application of the estrogen threshold hypothesis to the physiologic hypoestrogenemia of lactation. Breastfeed Med. 2015;10(2):77-83. DOI:10.1089/bfm.2014.0030
14. Gustavino C, Sala P, Cusini N, et al. Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: A prospective randomised clinical trial. Ann Med. 2021;53(1):1589-97. DOI:10.1080/07853890.2021.1974083
15. Менопауза и климактерическое состояние у женщины. Клинические рекомендации РОАГ. 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/117_2. Ссылка активна на 16.05.2024 [Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Klinicheskie rekomendatsii ROAG. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/117_2. Accessed: 16.05.2024 (in Russian)].
16. Ekin M, Yaşar L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet. 2011;283(3):539-43. DOI:10.1007/s00404-010-1382-8
17. Jokar A, Davari T, Asadi N, et al. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: A randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016;4(1):69-78. PMID:26793732
18. Cox P, Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019;22(6):565-71. DOI:10.1080/13697137.2019.1643180
19. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74(3):220-3. DOI:10.1016/j.contraception.2006.03.022
20. Handy AB, McMahon LN, Goldstein I, Meston CM. Reduction in genital sexual arousal varies by type of oral contraceptive pill. J Sex Med. 2023;20(8):1094-102. doi:10.1093/jsxmed/qdad072
21. Cotangco K, Class QA, Johnson TP, Kothari R. Cervical cancer survivors' attitudes and understanding of menopause and hormone therapy. Menopause. 2020;27(6):701-5. DOI:10.1097/GME.0000000000001520
22. Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: Incidence and survival across European Countries. Breast Care (Basel). 2019;14(6):344-53. DOI:10.1159/000503219
23. Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol. 2022;13(2):71-100. DOI:10.5306/wjco.v13.i2.71
24. Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647-61. DOI:10.1210/jc.2017-01138
25. Kingsberg SA, Larkin L, Krychman M, et al. WISDOM survey: Attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. 2019;26(2):124-31. DOI:10.1097/GME.0000000000001194
26. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. DOI:10.1097/GME.0000000000001609
27. Shah MB, Hoffstetter S. Contraception and sexuality. Minerva Ginecol. 2010;62(4):331-47. PMID:20827250
28. Casey PM, MacLaughlin KL, Faubion SS. Impact of contraception on female sexual function. J Womens Health (Larchmt). 2017;26(3):207-13. DOI:10.1089/jwh.2015.5703
29. Журавлева Ю.А., Прохорова О.В., Гептинг Н.А., и др. Женская сексуальность и комбинированные оральные контрацептивы: проблемы и возможности коррекции. Российский вестник акушера-гинеколога. 2020;20(6):101-6 [Zhuravleva JA, Prokhorova OV, Gepting NA, et al. Female sexuality and combined oral contraceptive pills: Administration and correction issues. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(6):101-6 (in Russian)]. DOI:10.17116/rosakush202020061101
30. Krapf JM, Mitchell L, Holton MA, Goldstein AT. Vulvar lichen sclerosus: Current perspectives. Int J Womens Health. 2020;12:11-20. DOI:10.2147/IJWH.S191200
31. Singh N, Ghatage P. Etiology, clinical features, and diagnosis of vulvar lichen sclerosus: A scoping review. Obstet Gynecol Int. 2020;2020:7480754. DOI:10.1155/2020/7480754
32. Шперлинг Н.В., Шперлинг М.И. Лечение и профилактика рецидивирования склероатрофического лихена половых органов у женщин. Акушерство и гинекология. 2022;12:70-8 [Shperling NV, Shperling MI. Treatment and prevention of recurrent genital lichen sclerosus in women. Obstetrics and Gynecology. 2022;12:70-8 (in Russian)]. DOI:10.18565/aig.2022.280
33. Van der Meijden WI, Boffa MJ, Ter Harmsel B, et al. 2021 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2022;36(7):952-72. DOI:10.1111/jdv.18102
34. Лишай красный плоский. Клинические рекомендации. 2020. Режим доступа: https://cnikvi.ru/docs/klinicheskie-rekomendacii/КР%20КПЛ%202020.docx. Ссылка активна на 16.05.2024 [Lishai krasnyi ploskii. Klinicheskie rekomendatsii. 2020. Available at: https://cnikvi.ru/docs/klinicheskie-rekomendacii/КР%20КПЛ%202020.docx. Accessed: 16.05.2024 (in Russian)].
35. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-6. DOI:10.1046 j.1365-2133.2000.03473.x
36. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808-14. DOI:10.1111/j.1365-2133.2011.10449.x
37. Dreisler E, Kjer JJ. Asherman's syndrome: Current perspectives on diagnosis and management. Int J Womens Health. 2019;11:191-8. DOI:10.2147/IJWH.S165474
38. Lee WL, Liu CH, Cheng M, et al. Focus on the primary prevention of intrauterine adhesions: Current concept and vision. Int J Mol Sci. 2021;22(10):5175. DOI:10.3390/ijms22105175
39. Tafti SZG, Javaheri A, Firoozabadi RD, et al. Role of hyaluronic acid intrauterine injection in the prevention of Asherman's syndrome in women undergoing uterine septum resection: An RCT. Int J Reprod Biomed. 2021;19(4):339-46. DOI:10.18502/ijrm.v19i4.9060
40. Huang CY, Chang WH, Cheng M, et al. Crosslinked hyaluronic acid gels for the prevention of intrauterine adhesions after a hysteroscopic myomectomy in women with submucosal myomas: A prospective, randomized, controlled trial. Life (Basel). 2020;10(5):67. DOI:10.3390life10050067
41. Wang YQ, Song XH, Wu SL, et al. Comparison of autocross-linked hyaluronic acid gel and intrauterine device for preventing intrauterine adhesions in infertile patients: A randomized clinical trial. Gynecol Minim Invasive Ther. 2020;9(2):74-80. DOI:10.4103/GMIT.GMIT_103_19
________________________________________________
2. Lev-Sagie A. Vulvar and vaginal atrophy: Physiology, clinical presentation, and treatment considerations. Clin Obs Gynecol. 2015;58(3):476-91. DOI:10.1097/GRF.0000000000000126
3. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. DOI:10.4065/mcp.2009.0413
4. Alvisi S, Gava G, Orsili I, et al. Vaginal health in menopausal women. Medicina (Kaunas). 2019;55(10):615. DOI:10.3390/medicina55100615
5. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62(4 Suppl. 1):45-51. DOI:10.1016/s0090-4295(03)00676-9
6. Escobar C, Rosenblum N. Vaginal estrogen – what a urologist should know. Urology. 2021;151:37-43. DOI:10.1016/j.urology.2020.05.034
7. Bayer IS. Hyaluronic acid and controlled release: A review. Molecules. 2020;25(11):2649. DOI:10.3390/molecules25112649
8. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528-39. DOI:10.1038/nrc1391
9. Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018;10(7):701. DOI:10.3390/polym10070701
10. Leeman LM, Rogers RG. Sex after childbirth: Postpartum sexual function. Obstet Gynecol. 2012;119(3):647-55. DOI:10.1097/AOG.0b013e3182479611
11. Banaei M, Azizi M, Moridi A, et al. Sexual dysfunction and related factors in pregnancy and postpartum: A systematic review and meta-analysis protocol. Syst Rev. 2019;8(1):161. DOI:10.1186/s13643-019-1079-4
12. Rowland M, Foxcroft L, Hopman WM, Patel R. Breastfeeding and sexuality immediately postpartum. Can Fam Physician. 2005;51(10):1366-7. PMID:16926969
13. Agarwal SK, Kim J, Korst LM, Hughes CL. Application of the estrogen threshold hypothesis to the physiologic hypoestrogenemia of lactation. Breastfeed Med. 2015;10(2):77-83. DOI:10.1089/bfm.2014.0030
14. Gustavino C, Sala P, Cusini N, et al. Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: A prospective randomised clinical trial. Ann Med. 2021;53(1):1589-97. DOI:10.1080/07853890.2021.1974083
15. Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Klinicheskie rekomendatsii ROAG. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/117_2. Accessed: 16.05.2024 (in Russian).
16. Ekin M, Yaşar L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet. 2011;283(3):539-43. DOI:10.1007/s00404-010-1382-8
17. Jokar A, Davari T, Asadi N, et al. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: A randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016;4(1):69-78. PMID:26793732
18. Cox P, Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019;22(6):565-71. DOI:10.1080/13697137.2019.1643180
19. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74(3):220-3. DOI:10.1016/j.contraception.2006.03.022
20. Handy AB, McMahon LN, Goldstein I, Meston CM. Reduction in genital sexual arousal varies by type of oral contraceptive pill. J Sex Med. 2023;20(8):1094-102. doi:10.1093/jsxmed/qdad072
21. Cotangco K, Class QA, Johnson TP, Kothari R. Cervical cancer survivors' attitudes and understanding of menopause and hormone therapy. Menopause. 2020;27(6):701-5. DOI:10.1097/GME.0000000000001520
22. Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: Incidence and survival across European Countries. Breast Care (Basel). 2019;14(6):344-53. DOI:10.1159/000503219
23. Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol. 2022;13(2):71-100. DOI:10.5306/wjco.v13.i2.71
24. Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647-61. DOI:10.1210/jc.2017-01138
25. Kingsberg SA, Larkin L, Krychman M, et al. WISDOM survey: Attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. 2019;26(2):124-31. DOI:10.1097/GME.0000000000001194
26. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. DOI:10.1097/GME.0000000000001609
27. Shah MB, Hoffstetter S. Contraception and sexuality. Minerva Ginecol. 2010;62(4):331-47. PMID:20827250
28. Casey PM, MacLaughlin KL, Faubion SS. Impact of contraception on female sexual function. J Womens Health (Larchmt). 2017;26(3):207-13. DOI:10.1089/jwh.2015.5703
29. Zhuravleva JA, Prokhorova OV, Gepting NA, et al. Female sexuality and combined oral contraceptive pills: Administration and correction issues. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(6):101-6 (in Russian). DOI:10.17116/rosakush202020061101
30. Krapf JM, Mitchell L, Holton MA, Goldstein AT. Vulvar lichen sclerosus: Current perspectives. Int J Womens Health. 2020;12:11-20. DOI:10.2147/IJWH.S191200
31. Singh N, Ghatage P. Etiology, clinical features, and diagnosis of vulvar lichen sclerosus: A scoping review. Obstet Gynecol Int. 2020;2020:7480754. DOI:10.1155/2020/7480754
32. Shperling NV, Shperling MI. Treatment and prevention of recurrent genital lichen sclerosus in women. Obstetrics and Gynecology. 2022;12:70-8 (in Russian). DOI:10.18565/aig.2022.280
33. Van der Meijden WI, Boffa MJ, Ter Harmsel B, et al. 2021 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2022;36(7):952-72. DOI:10.1111/jdv.18102
34. Lishai krasnyi ploskii. Klinicheskie rekomendatsii. 2020. Available at: https://cnikvi.ru/docs/klinicheskie-rekomendacii/КР%20КПЛ%202020.docx. Accessed: 16.05.2024 (in Russian).
35. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-6. DOI:10.1046 j.1365-2133.2000.03473.x
36. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808-14. DOI:10.1111/j.1365-2133.2011.10449.x
37. Dreisler E, Kjer JJ. Asherman's syndrome: Current perspectives on diagnosis and management. Int J Womens Health. 2019;11:191-8. DOI:10.2147/IJWH.S165474
38. Lee WL, Liu CH, Cheng M, et al. Focus on the primary prevention of intrauterine adhesions: Current concept and vision. Int J Mol Sci. 2021;22(10):5175. DOI:10.3390/ijms22105175
39. Tafti SZG, Javaheri A, Firoozabadi RD, et al. Role of hyaluronic acid intrauterine injection in the prevention of Asherman's syndrome in women undergoing uterine septum resection: An RCT. Int J Reprod Biomed. 2021;19(4):339-46. DOI:10.18502/ijrm.v19i4.9060
40. Huang CY, Chang WH, Cheng M, et al. Crosslinked hyaluronic acid gels for the prevention of intrauterine adhesions after a hysteroscopic myomectomy in women with submucosal myomas: A prospective, randomized, controlled trial. Life (Basel). 2020;10(5):67. DOI:10.3390life10050067
41. Wang YQ, Song XH, Wu SL, et al. Comparison of autocross-linked hyaluronic acid gel and intrauterine device for preventing intrauterine adhesions in infertile patients: A randomized clinical trial. Gynecol Minim Invasive Ther. 2020;9(2):74-80. DOI:10.4103/GMIT.GMIT_103_19
Авторы
В.Н. Прилепская, Н.М. Назарова*, А.Р. Девяткина, П.Р. Абакарова, Е.А. Межевитинова
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России, Москва, Россия
*n_nazarova@oparina4.ru
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*n_nazarova@oparina4.ru
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России, Москва, Россия
*n_nazarova@oparina4.ru
________________________________________________
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*n_nazarova@oparina4.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.